达到国家质量指标基准可减少非肌层浸润性膀胱癌的复发和进展
在苏格兰国家医疗服务体系(NHS)质量绩效指标(QPI)项目中,12家合作中心前瞻性收集2014年4月1日至2017年3月31日新诊断膀胱癌患者数据,其中2688例为非肌层浸润性膀胱癌(NMIBC),中位随访60.3个月。达到首次经尿道膀胱肿瘤电切术(TURBT)中采样逼尿肌(DM)目标及TURBT后单次灌注丝裂霉素C(SI-MMC)目标的医院,其NMIBC患者复发和进展时间均显著延长。
要点
- 达到逼尿肌采样目标的医院5年复发率较未达标医院低5.4%(38.9% vs 44.3%)。
- 接受单次丝裂霉素C灌注者复发率较未接受者低20.4%(35.4% vs 55.8%)。
- 达到逼尿肌采样目标和单次丝裂霉素C灌注均与无复发生存和无进展生存显著改善独立相关。
核心结论
- 在全国QPI项目真实世界中,达到逼尿肌采样和单次丝裂霉素C灌注目标与NMIBC患者复发和进展延迟独立相关。
研究设计与样本
- 苏格兰NHS于2014年4月全国强制执行膀胱癌QPI,NHS健康委员会前瞻性收集所有新发膀胱癌患者数据,并汇总12家合作中心的前瞻性监测数据。
- 2014年4月1日至2017年3月31日共诊断3899例新发膀胱癌,其中2688例为NMIBC。
- 中位随访60.3个月;采用Kaplan-Meier法和Cox多变量回归分析。
主要发现
- 达到逼尿肌采样目标的医院5年复发率较未达标医院低5.4%(442/1136[38.9%] vs 677/1528[44.3%],95%CI 1.6-9.2,p=0.005)。
- 单次丝裂霉素C灌注与复发率降低20.4%相关(634/1791[35.4%] vs 469/840[55.8%],95%CI 16.4-24.5,p<0.001)。
- Cox多变量回归中,达到逼尿肌采样目标与复发改善相关(HR 0.81,95%CI 0.73-0.91,p=0.0002),单次丝裂霉素C灌注与复发改善相关(HR 0.66,95%CI 0.59-0.74,p<0.004)。
- 达到逼尿肌采样目标与无进展生存改善相关(HR 0.62,95%CI 0.45-0.84,p=0.002),单次丝裂霉素C灌注与无进展生存改善相关(HR 0.65,95%CI 0.49-0.87,p=0.004)。
关键数值与推荐
- 关注的QPI为:(1)医院在首次TURBT中达到逼尿肌采样目标;(2)TURBT后使用单次丝裂霉素C灌注。
临床怎么用
- 在全国QPI项目真实世界中,达到逼尿肌采样和单次丝裂霉素C灌注目标与NMIBC患者复发和进展延迟独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noncompliance with evidence-based interventions and guidelines contributes to significant and variable recurrence and progression in patients with non-muscle-invasive bladder cancer (NMIBC). The implementation of a quality performance indicator (QPI) programme in Scotland's National Health Service (NHS) aimed to improve cancer outcomes and reduce nationwide variance. OBJECTIVE: To evaluate the effect of hospitals achieving benchmarks for two specific QPIs on time to recurrence and progression in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: QPIs for bladder cancer (BC) were enforced nationally in April 2014. NHS health boards collected prospective data on all new BC patients. Prospectively recorded surveillance data were pooled from 12 collaborating centres. INTERVENTION: QPIs of interest were (1) hospitals achieving detrusor muscle (DM) sampling target at initial transurethral resection of bladder tumour (TURBT) and (2) use of single instillation of mitomycin C after TURBT (SI-MMC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary and secondary endpoints were time to recurrence and progression, respectively. Kaplan-Meier and Cox multivariable regression analyses were performed. KEY FINDINGS AND LIMITATIONS: Between April 1, 2014 and March 31, 2017, we diagnosed 3899 patients with new BC, of which 2688 were NMIBC . With a median follow up of 60.3 mo, hospitals achieving the DM sampling target had a 5.4% lower recurrence rate at 5 yr than hospitals not achieving this target (442/1136 [38.9%] vs 677/1528 [44.3%], 95% confidence interval [CI] = 1.6-9.2, p = 0.005). SI-MMC was associated with a 20.4% lower recurrence rate (634/1791 [35.4%] vs 469/840 [55.8%], 95% CI = 16.4-24.5, p < 0.001). On Cox multivariable regression, meeting the DM target and SI-MMC were associated with significant improvement in recurrence (hazard ratio [HR] 0.81, 95% CI = 0.73-0.91, p = 0.0002 and HR 0.66, 95% CI = 0.59-0.74, p < 0.004, respectively) as well as progression-free survival (HR 0.62, 95% CI = 0.45-0.84, p = 0.002 and HR 0.65, 95% CI = 0.49-0.87, p = 0.004, respectively). We did not have a national multicentre pre-QPI control. CONCLUSIONS: Within a national QPI programme, meeting targets for sampling DM and SI-MMC in the real world were independently associated with delays to recurrence and progression in NMIBC patients. PATIENT SUMMARY: Following the first 3 yr of implementing a novel quality performance indicator programme in Scotland, we evaluated compliance and outcomes in non-muscle-invasive bladder cancer. In 2688 patients followed up for 5 yr, we found that achieving targets for sampling detrusor muscle and the single instillation of mitomycin C during and after transurethral resection of bladder tumour, respectively, were associated with delays in cancer recurrence and progression.
引用
- Mariappan P, Johnston A, Trail M, et al. Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024. PMID: 38296735. doi:10.1016/j.euo.2024.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。